Oncolys BioPharma总裁浦田泰生（Yasuo Urata）在公司针对食管癌的病毒疗法获得批准后，回顾了漫长的研发过程。
该疗法被称为世界首款病毒疗法。浦田表示，希望它能改善食管癌患者的生活质量。
此次获批标志着这家总部位于日本的制药公司长期努力的成果。现有报告中未具体说明该疗法的详细作用机制。
《日本时报》于2026年6月18日发布了相关报道。
Oncolys总裁回顾世界首款癌症疗法的研发历程
由 AI 报道
相关文章
AI 生成的图像
AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial
由 AI 报道 AI 生成的图像 事实核查
A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.
A Japanese health panel has approved national health insurance coverage for Sumitomo Pharma's Amchepry, an iPS cell-derived treatment for Parkinson’s disease. The move makes it the world's first commercialized medical product from iPS cells.
由 AI 报道
BioInvent International AB held a key opinion leader event on May 27, 2026, to discuss ovarian cancer treatments and TNFR2-targeted therapies.
Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.
June 09, 2026 17:25